GLP1_NEW
Exenatide extended release and dapagliflozin 2 to 10 mg injection once weekly
DAPAEXEN_SC_2-10MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Dapagliflozin | MD -0.58 (-1.51 to 0.44) | 0.81 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.45 (-1.99 to -0.89) | 0.90 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 6.95 (1.51 to 20.14) | 0.71 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -5.77 (-8.75 to -2.85) | 0.89 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -5.09 (-8.91 to -0.99) | 0.76 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.03 (0.52 to 2.07) | 0.47 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.84 (0.38 to 1.88) | 0.80 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.08 (0.38 to 2.85) | 0.73 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.11 (0.50 to 2.40) | 0.65 |